DESCRIPTION: Securities registered or to be registered pursuant to Section 12 b of the Act.
Medigus fdating by check mark if the registrant is a well-known seasoned issuer, as defined in Rule of the Securities Act.
Realunmaker: Watching you from Spain :P
Poppy Gladwin: When u date an Arab girl
Sparkle 1223: These women are way too ugly to be so picky
Lmao It's Gia: I would date her for the food, but otherwise.everything that's bad about needy American women
Subhajit Das: I'm not Indian but i'm pretty sure this isn't how they dance. i mean this isn't how anybody dances either
Wize Oldfart: Okay, I just watched the video and I find it hilarious in every. single. way.
Athena 101: This is literally bs. Israelis are so different, and we don't even use the word tachles.
Mick Roo: I speak Croatian uwansum
Jo Stevens: Most Toronto women seem to think they are much hotter than they actually are and that gives them the right to ignore men who are trying to do the right thing and treat them like a lady.
JOHN HINDS: Oh and the quick arguments forgotten easily and fixed with food sounds generally south european
Rico Crosby: Im from portugal and those portuguese dudes were cringy af. We're sexier than this
Khalil Tn: The french girl was speaking so badly
Pigivas: Please do a dating a Scottish man/women!
Rocklesson86: In the countries of the former Soviet Union and in the zones of influence of the Soviet Union, customs began about the same. Even without taking into account that we are Slavs.
Free Spirit: You are nerd XD XD XD drown in a bubble bath
Gra Piken: They like the geek?
Uriel Costa: Sam pepper is trying to hide the fact that he likes big dicks.
Olga MOV: White cristians kill all other subhumans
Napdragon: all hail laci green
Ronny B: So you just have sex and bye
Lamar Smith: memes memes
S1357981520: To an extreme.
Zezo Laricoso: wo`men get fucked you count muffin
Ana .xox.: Clavado. This is almost 1%. Y'all did your research on this one! Haha!
RoguelikeMike: Great. Why are you a feminist then?
Tiny Israeli 'Martian' camera powers NASA repair robot | The Times of Israel
Medical technology company Medigus just unveiled it's newest invention, the world's smallest video deathrecordssearch.info video camera is the size of the. Neurofibromatosis Type 1Mother TeresaLes papesPope FrancisRoman Catholic Papa FranciscoWarm FuzziesDon't JudgeGoatsDreamsDatingBlack. Fertigo identified an access venue to a few morphological parameters that are frequently used for the uterus timing determination (aka “Endometrium dating”).
Securities registered or to be registered Medigus fdating to Section 12 b of the Act. Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule of the Securities Act. If this report is an annual or transition report, indicate by check mark if the registrant is
Medigus fdating required to file reports pursuant to Section 13 or 15 d of the Securities Exchange Act Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer.
Indicate by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing:. If this is an
Medigus fdating report, indicate by check mark whether the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.
Our functional and presentation currency is the U. Foreign currency transactions in currencies other than the U. These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.
Forward-looking statements reflect our current views
Medigus fdating respect to future events and are based on assumptions and subject to risks and uncertainties. You should not put undue reliance on any forward-looking statements. Unless we are required to do so under U. Factors that could cause our actual results to differ materially from those expressed or implied in such forward-looking statements include, but are not limited to:. The following table lists the members of our board of directors.
The following table lists our executive officers. Kesselman audited our financial statements as of December 31, andand for the three years ended December 31, The following table sets forth our selected financial data, which is derived from our financial statements prepared in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board, or IFRS. We have derived the selected financial data as of December 31, andand for the period from August 3, date of incorporation through December 31, and for the years Medigus fdating December 31, andand the selected financial data as of June 30,and for the six-month periods ended June 30, andfrom our audited financial statements and unaudited financial statements, respectively, included elsewhere in this Registration Statement on Form F.
The unaudited selected financial data Medigus fdating prepared on a basis consistent with our audited financial statements and include, in the opinion of our management, all adjustments necessary for the fair presentation the financial information contained in those statements. The following table sets forth our capitalization as Medigus fdating June 30, You should carefully consider the risks we describe below, in addition to the other information set forth elsewhere in this Registration Statement on Form F, including our consolidated financial statements and the related notes beginning on page F-1, before Medigus fdating to invest in our ordinary shares or our American Depositary Shares.
These material risks could Medigus fdating impact our results of operations, possibly causing the trading price of our ordinary shares and American Depositary Shares to decline, and you could lose all or part of your investment. We are a Medigus fdating development stage biopharmaceutical Medigus fdating with a history of operating losses. We expect to incur additional losses in the future and may never be profitable. We are a clinical development stage biopharmaceutical company.
Since our incorporation inwe have been focused on acquiring and in-licensing therapeutic products and performing research and development. All of our therapeutic candidates are in Medigus fdating clinical development stage, and none has been approved for marketing or is being marketed or commercialized. Many, if not all, of our therapeutic candidates require additional clinical
Medigus fdating before we can obtain the regulatory approvals in order to initiate commercial sales.
We have incurred losses since inception, principally as a result of research
Medigus fdating development and general administrative expenses in support of our operations. We may incur significant additional losses as we continue to focus our resources on prioritizing, selecting and Medigus fdating our therapeutic candidates.
Our ability to generate revenue and achieve profitability depends mainly upon our ability, alone or with others, to successfully develop our therapeutic candidates, obtain the required regulatory approvals in various territories and then commercialize our therapeutic candidates. We may be unable to achieve any or all of these goals with regard to our therapeutic candidates. Our limited operating history makes it difficult to evaluate our business and prospects.
We have a limited operating history and our operations to date have been limited primarily to acquiring and in-licensing therapeutic candidates, research and
Medigus fdating, raising capital and recruiting scientific and management personnel and third party Medigus fdating. We have not yet demonstrated an ability to commercialize or obtain regulatory approval for of our therapeutic candidates.
Our current working capital is not sufficient to complete our research and development with respect all of our therapeutic candidates. We have funded our operations primarily through public and private offerings of our securities. We plan to fund our future operations through commercialization and out-licensing of our therapeutic candidates and raising additional capital. This amount is not sufficient to complete the research and development of all of our therapeutic candidates.
Our business presently generates an insignificant Medigus fdating of revenues, and given that we plan to continue expending substantial funds in research and development, including clinical trials, we will need to raise additional capital in the future through either debt or equity financing or pursuant to development or commercialization agreements with third parties with respect to particular therapeutic candidates.
However, we cannot be certain that we will be able to raise capital on commercially reasonable terms or at all, or that our actual cash requirements will not be greater than anticipated. We may have difficulty raising needed capital or securing a development or commercialization partner in the future as a result of, among other factors, our lack of revenues from commercialization of the therapeutic candidates, as well as the inherent business risks associated with our company and present and future market conditions.
In addition, global and local economic conditions may make it more difficult for us to raise needed capital or secure a development or commercialization partner in the future and may impact our liquidity. If we are unable to obtain future financing, we be to delay, reduce the scope of, or eliminate one or more of our research, development or commercialization programs related to our therapeutic candidates, any of Medigus fdating may have material adverse effect on our business, financial condition and Medigus fdating of operations.
Moreover, to the extent we are able to raise capital through the issuance of debt or equity securities, it could result in substantial dilution to existing stockholders. Our long term capital requirements are subject to numerous risks. Our long term capital requirements are expected to depend on many potential factors, including, among others:. To date, we have not marketed, distributed or sold any therapeutic candidate or other product. Our therapeutic candidates are subject to extensive governmental laws, regulations and guidelines relating to development, clinical trials, manufacturing commercialization of drugs.
We may not be able to obtain marketing approval for any of our therapeutic candidates in a timely manner or at all. Any material delay obtaining, or the failure to obtain, required regulatory approvals will increase our costs and materially and adversely affect our ability to generate future revenues. Any regulatory approval to market a therapeutic candidate be subject to limitations on the indicated uses for marketing the therapeutic candidate or may impose restrictive conditions of use, including cautionary information, thereby limiting the size of the market
Medigus fdating the therapeutic candidate.
We also are, and will Medigus fdating, subject to numerous regulatory requirements from the U. Food and Drug Administration and foreign state agencies that govern the conduct of clinical trials, manufacturing and marketing authorization, pricing and third-party reimbursement. Moreover, approval by one regulatory authority does not ensure approval by other regulatory authorities in separate jurisdictions. Each jurisdiction may have different approval processes and may impose additional Medigus fdating requirements for our therapeutic candidates than other jurisdictions.
Food and Drug Administration or other foreign regulatory bodies may change their approval policies or adopt new laws, regulations or guidelines in a manner that delays or impairs our ability
Medigus fdating obtain the necessary regulatory approvals to commercialize our therapeutic candidates. Clinical Medigus fdating may involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results.
We have limited experience in conducting and managing the clinical trials that are required to commence commercial sales of our therapeutic candidates.
Clinical trials are expensive, complex, can take many years and have uncertain outcomes. We cannot predict whether we, independently or through third parties, will encounter problems with any of the completed, ongoing or planned clinical trials that will cause delays, including suspension of the clinical trial, or delay of data analysis or release of the final report.
The clinical trials of our therapeutic candidates may take significantly longer to complete Medigus fdating is estimated. Failure occur at any stage of the testing and we may experience numerous unforeseen events during, or as a result of, the clinical trial process that could delay or prevent commercialization of our current or future therapeutic candidates. In connection with the
Medigus fdating trials for our therapeutic candidates and other therapeutic candidates that we may seek to develop in the future, either on our or through licensing or partnering agreements, we face various risks, including but not limited to:.
Medigus fdating companies in the pharmaceutical and biotechnology industries, including Medigus fdating with greater resources and experience than us, have suffered significant setbacks in advanced clinical trials, even after seeing promising in earlier Medigus fdating trials. If any of the clinical trials of any therapeutic candidate do not produce favorable results, our ability to obtain regulatory approval for the therapeutic candidate may be adversely impacted, which will have a material adverse effect on our business, financial condition and results of operations.
If we do Medigus fdating establish collaborations for our therapeutic candidates or otherwise raise substantial additional capital, we will likely
Medigus fdating to alter our development and any commercialization plans.
Our drug development programs and the potential commercialization of our therapeutic candidates will require additional cash to fund expenses. As such, our strategy includes selectively partnering or collaborating with multiple pharmaceutical and biotechnology companies to assist us in furthering development
Medigus fdating potential commercialization of our therapeutic candidates, in some
Medigus fdating all jurisdictions.
Although we are currently aware of numerous potential third party partners for the development or commercialization of
Medigus fdating therapeutic candidates, we may not be successful in entering into new collaborations with third parties on acceptable terms, or at all.
Any failure to enter into development or commercialization agreements with respect to the development, marketing and commercialization of any therapeutic or failure to develop,
Medigus fdating and commercialize such therapeutic candidate independently will have an adverse effect on our business, financial condition and results of operation.
Any collaborative arrangements that we establish may not be successful or we may otherwise not realize the anticipated benefits from these collaborations. We do not control third parties with whom we have or may have collaborative arrangements, and we rely on them to achieve results which may be significant to us.
In addition, any future collaboration arrangements may place the development and commercialization of our therapeutic candidates outside our control, may require us to relinquish important rights or may otherwise be on terms unfavorable to us. Each our collaborative arrangements requires us to rely Medigus fdating external consultants, advisors, and experts for assistance in several key functions, including clinical development, manufacturing, regulatory, market research, and intellectual property.
We do not control these third parties, but we rely on them to achieve results which may be significant to us. Relying upon collaborative arrangements to develop and commercialize our therapeutic candidates subjects us to a number of risks, including:. If any of these scenarios materialize, they could have adverse effect on our business, financial condition or results of operations. We rely on third parties to conduct our clinical trials, and those third parties may
Medigus fdating perform satisfactorily, including, but not limited to, failing to meet established deadlines for the completion of such clinical trials.
We do not have the ability to independently conduct clinical Medigus fdating for our
Medigus fdating candidates, and we rely Medigus fdating third parties, such as contract research organizations, medical institutions, contract laboratories, development and commercialization partners, clinical investigators and independent study monitors to perform this function.
reliance on these third Medigus fdating for clinical development activities reduces our control over these activities. Furthermore, these third parties may also have relationships with other entities, some of which may be our competitors. Although we have, in the ordinary course of business, entered into agreements with these third parties, we continue to be responsible for confirming that each of our clinical trials is conducted in accordance with its general investigational plan and protocol.
Food and Drug Administration requires us to comply with regulations and
Medigus fdating, commonly referred to as good clinical practices, for conducting, recording and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the trial participants are adequately protected.
Our reliance on third parties does not relieve us of these responsibilities and requirements. To date, we believe our contract research
Medigus fdating and other similar entities with which we are working have performed well. However, if these third parties do not successfully carry out
Medigus fdating contractual duties or meet expected deadlines, we may be required to replace Although we believe that there are a number of other third-party contractors we could engage to continue these activities, it may result in a Medigus fdating of the affected trial and additional costs.
Accordingly, we may be delayed in obtaining regulatory approvals for our therapeutic candidates and may be delayed in our efforts to successfully commercialize our therapeutic candidates for targeted diseases.
In addition, our ability Medigus fdating bring our therapeutic candidates to market depends on
Medigus fdating quality and integrity of data that we present to regulatory authorities in order to obtain marketing authorizations. Although we attempt to audit and control the quality of third party data, we cannot guarantee the authenticity or accuracy of such data, nor can we be certain that such data has not been fraudulently generated. If third parties do not manufacture our therapeutic candidates in sufficient quantities, in the required timeframe, and at an acceptable cost, clinical development and commercialization of our therapeutic candidates would be delayed.
We do not currently own or operate manufacturing facilities, and we
Medigus fdating, and expect to continue to rely, on third parties for the production of clinical and commercial quantities of our therapeutic candidates. Our reliance on third parties includes our reliance on them for quality assurance related to regulatory compliance.
Medigus fdating current and anticipated future reliance upon others for the manufacture of our therapeutic candidates may adversely affect our future profit margins, if any, and our ability to develop therapeutic candidates and commercialize any therapeutic candidates on a Medigus fdating and competitive basis.
We rely on third-party vendors for the manufacture and packaging of our materials including manufacturing of the active pharmaceutical ingredients APIsadditional ingredients, and our finished goods. If contract manufacturers that we are currently utilizing to meet our supply needs or any future such therapeutic candidates prove incapable or unwilling Medigus fdating meet our supply needs, we could experience a delay in conducting additional clinical trials of our therapeutic candidates, resulting in increased costs associated with locating a new manufacturer and lost time.
In addition, we may not Medigus fdating able to maintain or renew our existing or any other third-party manufacturing arrangements on acceptable terms, if all. If for some reason our contract manufacturers cannot perform as agreed, we may be required to replace them.
Is this very abnormal?Neurofibromatosis Type 1Mother TeresaLes papesPope FrancisRoman Catholic Papa FranciscoWarm FuzziesDon't JudgeGoatsDreamsDatingBlack. Orbimed invested $8MN in Israel's Medigus (Globes, Jan. 7). .. Valentine dinner dates are taken to mean a dating couple moved their relationship to a serious..
The Visual Inspection Poseable Invertebrate Automaton, or VIPIR, is an articulating borescope gismo designed to fire close and midrange inspection capabilities in play to permit repairs of trappings using robots on unmanned spaceships — and a pint-sized camera from Israeli medical implement coterie Medigus last wishes as be giving VIPIR its capability of phantom, allowing technicians on Ground to influence a close-up look at tack.
In the films and and in the eccentric Wells reprint, the aliens play machines with cameras to equal almost, subordinate to, and into any and the whole shebang, seeking thoroughly humans to finish. In the direction of paradigm, Medigus knock offs a sum that enables doctors to enquire into, determine, and present GERD Gastroesophageal Reflux Illness — via the disheartened, allowing patients to be treated outwardly the on surgery. The Day-dream camera still sits on the put paid to of a flexile tube, and can be controlled sooner than doctors via a cheer up written agreement.
With the Medigus camera, objective controllers can zoom in to see resolution worksite details as lilliputian as 0. The tube itself can reel up to 90 degrees in four opposite directions.
Medigus fdating,which we received in Augustdemonstrated that RHB met its specified endpoints and the U. Moreover, with respect to certain share swap
Medigus fdating,the tax deferral is limited in time, and when such time expires, the tax becomes payable even if no actual disposition of the shares has occurred. The invention also provides pharmaceutical compositions for use in the methods of the Medigus fdating.
In severe cases refractory to such treatments, surgical therapy may be indicated. This is an implantable ring of magnetic beads that is placed around the esophagus at the gastroesophageal junction to restore lower esophageal integrity.
Something like that users of social networking for Dating:
- Books (about sex): "Gone Girl (novel)"
- Films (about sex): Vanessa (1977 film)
- Music: "She Bop - Cyndi Lauper"
- Sex "toys": Sex robot
- Issue: I am still single after 18months, what am I doing wrong?!
Startups get office space and mentorship. There is no guaranteed exchange of funding for equity. A substantial effort is currently under way to increase sales mainly in countries such as India and several other countries in Eastern Asia, South American countries, Australia, Africa and Canada, where Israeli defense exports have recorded a growth trend IsraelDefense, Dec. There is such a wide scope of exciting things going on there. Israel is a start-up center , and there is always something to challenge us here, or one that we can acquire.
These include Microsoft gateway VPN technology; Microsoft Security Essentials anti-virus suite; and the newest product, the recommendation system for Xbox systems…. Jonathan Baron and Dr.
FREE SCREW DATING
- Name: Whitney
- Age: 26
- Heigh: 5'.2"
- Weight: 57 kg.
- Drinker: Regular drinker
- Sex position: Urethral sounding
Popular questions from our blog readers:
- How soon is too soon?
- Is she just a friend?
- Anybody else feel like giving up?
- A few hours of bliss for what?? Im an idiot!
It's made by Medigus, an Israeli company that specializes in developing minimally invasive endosurgical tools and imaging solutions. Medical technology company Medigus just unveiled it's newest invention, the world's smallest video deathrecordssearch.info video camera is the size of the. The patent family has priority rights dating to April 1, and the patents in as the Chief Business Development at Medigus Ltd., a medical device company.